1350 related articles for article (PubMed ID: 18463380)
61. [Mediator interactions in vasculogenesis and angiogenesis].
Pavlov KA; Shchegolev AI; Dan VN; Sapelkin SV; Mishnev OD
Angiol Sosud Khir; 2009; 15(2):31-5. PubMed ID: 19806936
[TBL] [Abstract][Full Text] [Related]
62. Vascular endothelial growth factor as a therapeutic target in cancer.
Bergsland EK
Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
[TBL] [Abstract][Full Text] [Related]
63. Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies.
Mahdi A; Darvishi B; Majidzadeh-A K; Salehi M; Farahmand L
J Cell Physiol; 2019 May; 234(5):5655-5663. PubMed ID: 30515806
[TBL] [Abstract][Full Text] [Related]
64. Comparative VEGF receptor tyrosine kinase modeling for the development of highly specific inhibitors of tumor angiogenesis.
Schmidt U; Ahmed J; Michalsky E; Hoepfner M; Preissner R
Genome Inform; 2008; 20():243-51. PubMed ID: 19425138
[TBL] [Abstract][Full Text] [Related]
65. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii S; Lyden D; Benezra R; Hattori K; Heissig B
Nat Rev Cancer; 2002 Nov; 2(11):826-35. PubMed ID: 12415253
[No Abstract] [Full Text] [Related]
66. Angiogenesis in spontaneous tumors and implications for comparative tumor biology.
Benazzi C; Al-Dissi A; Chau CH; Figg WD; Sarli G; de Oliveira JT; Gärtner F
ScientificWorldJournal; 2014; 2014():919570. PubMed ID: 24563633
[TBL] [Abstract][Full Text] [Related]
67. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.
Bikfalvi A; Bicknell R
Trends Pharmacol Sci; 2002 Dec; 23(12):576-82. PubMed ID: 12457776
[TBL] [Abstract][Full Text] [Related]
68. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
69. Vascular endothelial growth factor and its inhibitors.
Verheul HM; Pinedo HM
Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
[TBL] [Abstract][Full Text] [Related]
70. [The regulation of VEGFs/VEGFRs in tumor angiogenesis by Wnt/beta-catenin and NF-kappaB signal pathway].
Gao MN; Li Y
Sheng Li Ke Xue Jin Zhan; 2013 Feb; 44(1):72-4. PubMed ID: 23672008
[No Abstract] [Full Text] [Related]
71. Imaging tumor angiogenesis.
Red-Horse K; Ferrara N
J Clin Invest; 2006 Oct; 116(10):2585-7. PubMed ID: 17016553
[TBL] [Abstract][Full Text] [Related]
72. Breast tumour angiogenesis.
Fox SB; Generali DG; Harris AL
Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
[TBL] [Abstract][Full Text] [Related]
73. Notch signaling from tumor cells: a new mechanism of angiogenesis.
Li JL; Harris AL
Cancer Cell; 2005 Jul; 8(1):1-3. PubMed ID: 16023591
[TBL] [Abstract][Full Text] [Related]
74. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
75. Judah Folkman.
Adamis AP; Miller JW
Semin Ophthalmol; 2009; 24(3):128-9. PubMed ID: 19437346
[No Abstract] [Full Text] [Related]
76. Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor.
Islam A; Banerjee S; Kambhampati S; Baranda J; Banerjee S; Weston AP; Saxena NK; Banerjee SK
Front Biosci; 2006 Sep; 11():2336-48. PubMed ID: 16720317
[TBL] [Abstract][Full Text] [Related]
77. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC; Leenders WP
Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
[TBL] [Abstract][Full Text] [Related]
78. Antiangiogenic therapy and surgical practice.
John AR; Bramhall SR; Eggo MC
Br J Surg; 2008 Mar; 95(3):281-93. PubMed ID: 18278790
[TBL] [Abstract][Full Text] [Related]
79. Vascular endothelial growth factor as a target for antiangiogenic therapy.
Gordon MS
J Clin Oncol; 2000 Nov; 18(21 Suppl):45S-6S. PubMed ID: 11060326
[No Abstract] [Full Text] [Related]
80. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
